BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BI 1815368 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BI 1815368\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06962839-5344@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:BI 1815368: Phase 2 readout est. (NCT06962839)
DESCRIPTION:BI 1815368\, phase 2\, Diabetic Macular Edema.\nStudy: A Study 
 to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabe
 tic Macular Edema\nEstimated primary completion: 1 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bi-1815368#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06962839
URL:https://assetmemo.bio/drug/bi-1815368#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
